

# Allogeneic Cell Therapy Products

ANMD-MRS9-090 · Advanced Therapeutics & Biomanufacturing

A Global Sustainability Due Diligence & Market Research Study

History 2020–2024 · Base Year 2025 · Forecast 2025–2032 · Outlooks 2035 / 2040 / 2050 · Currency US\$

## WHY THIS REPORT

Allogeneic cell therapy products are the off-the-shelf future of cell medicine — the donor-derived and iPSC-derived CAR-T, NK-cell, MSC and gamma-delta T-cell therapies designed to be manufactured at scale and dosed on demand, rather than built per patient. This decision-grade study sizes the global market three ways — value, patients treated and dose volume — across product type, cell source and application, across seven regions and four scenarios to 2032, with outlooks to 2050.

## SUSTAINABILITY & SDG IMPACT — THE ANMD LENS

Sustainability is this report's backbone, not an afterthought. Allogeneic platforms' core contribution is access and affordability — scalable, off-the-shelf cell therapy at lower cost — alongside the footprint of cell manufacturing.

Mapped Sustainable Development Goals:

<p><b>SDG 3</b> Good Health &amp; Well-Being</p>	<p><b>SDG 9</b> Industry, Innovation &amp; Infrastructure</p>	<p><b>SDG 10</b> Reduced Inequalities</p>	<p><b>SDG 12</b> Responsible Consumption</p>	<p><b>SDG 17</b> Partnerships for the Goals</p>
--	---	---	--	---

Measurable sustainability outcomes assessed:

- Scalable, off-the-shelf access at lower cost
- Equitable patient access and affordability
- Manufacturing energy and single-use waste
- Cold-chain logistics and pricing as material risks

**Framework alignment:** Double materiality mapped to GRI, SASB, ISSB, TCFD, TNFD, CSRD and the EU Taxonomy, with greenwashing and SDG-washing screens applied throughout.

## WHAT'S INSIDE AT A GLANCE

<p><b>53</b> Chapters</p>	<p><b>9</b> Report Parts</p>	<p><b>7</b> Regions Covered</p>	<p><b>40+</b> Country Markets</p>
<p><b>2025–32</b> Forecast Horizon</p>	<p><b>4</b> Forward Scenarios</p>	<p><b>20+</b> Companies Profiled</p>	<p><b>5</b> SDGs Mapped</p>

## REPORT COVERAGE

**Geographic scope:** North America, Europe, Asia Pacific, Latin America, Africa, Middle East and Rest of World — with named country intelligence. North America leads the pipeline; Europe holds gene-editing strength; Asia Pacific is building capability; other regions assessed on their own merits.

## MARKET OVERVIEW

### From per-patient manufacturing to off-the-shelf supply — where cell therapy targets scale, speed and access.

Allogeneic cell therapy is an emerging, high-potential field. Demand is driven by the promise of off-the-shelf availability, lower cost-of-goods and scalable manufacturing — with persistence, immune rejection and gene editing central to viability. The market is read three ways — value, patients treated and dose volume — and forecast under four scenarios, each region reported separately.

- **North America leads the pipeline** — United States, across CAR-T, NK and iPSC platforms
- **Europe holds gene-editing strength** — Switzerland and France, enabling allogeneic engineering
- **Asia Pacific is building capability** — Japan and China, advancing allogeneic and iPSC programmes
- **Off-the-shelf manufacturing is the differentiator** — donor and iPSC sourcing decouple supply from the patient, targeting scale and cost

## REGIONAL OUTLOOK

Across seven reporting regions, the report separates leading markets from high-growth and emerging ones — each profiled in full rather than aggregated into Rest of World.

Region	Stage	Lead Markets & Drivers
North America	Pipeline leader	United States — CAR-T, NK & iPSC platforms
Europe	Gene-editing strength	Switzerland, France — allogeneic engineering
Asia Pacific	Building capability	Japan, China — regional iPSC programmes
Latin America	Frontier	Brazil — trial access
Africa	Frontier	South Africa — research access
Middle East	Emerging	Israel, UAE — research & investment

## KEY MARKET DRIVERS & RESTRAINTS

Drivers	Restraints
<ul style="list-style-type: none"> <li>• Off-the-shelf availability &amp; speed</li> <li>• Lower cost-of-goods vs autologous</li> <li>• Scalable iPSC &amp; donor manufacturing</li> <li>• Gene-editing-enabled engineering</li> <li>• Expansion across cell types (NK, MSC)</li> </ul>	<ul style="list-style-type: none"> <li>• Persistence &amp; durability vs autologous</li> <li>• Immune rejection &amp; host-versus-graft</li> <li>• Manufacturing &amp; differentiation complexity</li> <li>• Early clinical maturity &amp; TRL</li> <li>• Regulatory &amp; reimbursement uncertainty</li> </ul>

## SEGMENTATION SNAPSHOT

<b>By Product Type</b>	Allogeneic CAR-T · NK-cell · iPSC-derived · MSC / stromal-cell · gamma-delta T-cell
<b>By Cell Source</b>	Donor-derived · iPSC-derived · cord / tissue-derived
<b>By Application</b>	Oncology · rare / genetic disease · immunology & infectious disease
<b>By End User</b>	Hospitals · pharma / biotech · CDMOs · academia
<b>By Stage</b>	Clinical · preclinical
<b>By Business Model</b>	Product sales · CDMO services · licensing

## TABLE OF CONTENTS — PARTS & CHAPTERS

The full report is organised into nine parts across 53 chapters, listed below. Detailed sub-headings, country tables and directories are provided in the full report.

### Part I — Report Foundation, Discovery and Strategic Intelligence

- › Chapter 1. Scope, Methodology and Report Architecture
- › Chapter 2. Industry Discovery Summary — Allogeneic Cell Therapy Products
- › Chapter 3. Executive Intelligence and Decision Dashboard
- › Chapter 4. Strategic Findings, Materiality and Investment Verdict Preview

### Part II — Market Intelligence, Sizing, Forecasting and Segmentation

- › Chapter 5. Industry Overview and Market Evolution
- › Chapter 6. Market Dynamics
- › Chapter 7. Global Market Size and Forecast, 2020–2032
- › Chapter 8. Market Segmentation Analysis
- › Chapter 9. End-User and Demand-Side Intelligence
- › Chapter 10. Pricing, Cost and Commercial Model Intelligence

### Part III — Regional and Country Intelligence

- › Chapter 11. Global Regional Intelligence Framework
- › Chapter 12. North America Market Intelligence
- › Chapter 13. Europe Market Intelligence
- › Chapter 14. Asia Pacific Market Intelligence
- › Chapter 15. Latin America Market Intelligence
- › Chapter 16. Africa Market Intelligence
- › Chapter 17. Middle East Market Intelligence
- › Chapter 18. Rest of World Market Intelligence

### Part IV — Technology, Innovation and Category-Specific Intelligence

- › Chapter 19. Technology Landscape and Architecture
- › Chapter 20. Emerging and Next-Generation Technology Intelligence
- › Chapter 21. Category-Specific Intelligence Module
- › Chapter 22. Research, Innovation and Funding Landscape

## Part V — Company, Competition, Patent and Project Intelligence

- › Chapter 23. Competitive Landscape
- › Chapter 24. Company Profiles
- › Chapter 25. Mergers, Acquisitions, Partnerships and Ecosystem Intelligence
- › Chapter 26. Patent Landscape and Intellectual Property Intelligence
- › Chapter 27. Project, Deployment and Case-Study Intelligence

## Part VI — Sustainability, ESG, SDG, Climate and Natural-Capital Intelligence

- › Chapter 28. Sustainability Intelligence Suite
- › Chapter 29. ESG Intelligence and Double Materiality
- › Chapter 30. ESG and Sustainability Framework Alignment
- › Chapter 31. SDG Intelligence
- › Chapter 32. Carbon, Net-Zero and Climate-Mitigation Intelligence
- › Chapter 33. Water, Biodiversity and Natural-Capital Intelligence
- › Chapter 34. Circular Economy and Resource-Security Intelligence
- › Chapter 35. Social Impact, Human Capital and Community Intelligence
- › Chapter 36. Climate Risk, Adaptation and Resilience Intelligence

## Part VII — Supply Chain, Policy, Legal, Economics and Finance

- › Chapter 37. Value Chain, Supply Chain and Geopolitical Intelligence
- › Chapter 38. Policy, Regulation and Incentive Intelligence
- › Chapter 39. Legal, Contracting and Risk-Allocation Intelligence
- › Chapter 40. Unit Economics, CAPEX, OPEX and Return Analysis
- › Chapter 41. Investment, Sustainable Finance and Bankability Intelligence

## Part VIII — Scenario, Future Intelligence and Final Due Diligence Verdict

- › Chapter 42. Scenario Analysis and Future Intelligence
- › Chapter 43. Sustainability Due Diligence Framework and Data-Room Index
- › Chapter 44. Risk Register, RAG Rating and Anti-Greenwashing Screen
- › Chapter 45. Bottom-Line Verdict and Strategic Recommendations
- › Chapter 46. Implementation Roadmap and Stakeholder Playbooks

## Part IX — Annexes, Directories and Reference Material

- › Chapter 47. Methodology Annex
- › Chapter 48. Corporate Directory and Company Intelligence Annex
- › Chapter 49. Patent Directory and Patent Intelligence Annex
- › Chapter 50. Project Intelligence Annex
- › Chapter 51. Forecast Annex
- › Chapter 52. Sustainability KPI Annex
- › Chapter 53. Reference Annexes

## COMPETITIVE & INVESTMENT SNAPSHOT

The competitive field spans allogeneic pioneers, iPSC platforms and gene-editing enablers. Deal activity — gene-editing partnerships, iPSC-platform deals and CDMO build-out — signals a field racing toward scalable, off-the-shelf cell therapy.

### Representative players profiled in the full report:

Allogene Therapeutics, Inc. · Fate Therapeutics, Inc. · Gilead Sciences, Inc. · Century Therapeutics, Inc. · CRISPR Therapeutics AG · Cellectis S.A. · Sana Biotechnology, Inc. · and further profiled players across pioneers and gene-editing enablers.

**Investment intelligence:** venture, infrastructure, development, climate and blended finance, green bonds and sustainability-linked loans — culminating in a bankability assessment and a conditional investment view.

## KEY QUESTIONS THIS REPORT ANSWERS

---

- How large is the global allogeneic cell therapy market, and how fast will it grow to 2032?
- Which regions, countries and segments offer the strongest risk-adjusted opportunity?
- How does off-the-shelf manufacturing change value versus autologous therapy?
- Who leads, and where is the competitive and patent white space?
- Is the investment case bankable — and under what conditions?
- How does the category align with the SDGs, equitable access and manufacturing-footprint expectations?

## WHY ANMD — THE DIFFERENCE

---

*Most market studies stop at units and revenue. This report is built as a sustainability due diligence instrument — fusing market sizing with ESG, SDG, climate, water and natural-capital intelligence and a decision-ready bankability view in a single architecture.*

- **Triangulated sizing** — every market read three ways so value, volume and the physical-unit views reconcile rather than conflict.
- **Region-honest forecasting** — Latin America, Africa and the Middle East reported in full, never hidden inside Rest of World, every forecast resolved to the 2025 base year.
- **Integrated evidence base** — company, patent and project databases linked to the analysis, with published-filing patents and FTO treated as an indicator, not a legal conclusion.
- **No-fabrication discipline** — every estimate carries a data-confidence rating and disclosed sources; gaps are flagged for further diligence, never filled with invented numbers.
- **Anti-greenwashing rigour** — SDG-washing and greenwashing screens plus claim-substantiation checks built into the ESG and project analysis.
- **Decision-first structure** — 9 Parts and 53 Chapters culminating in stakeholder playbooks and a clear, conditional investment view.

## WHO SHOULD BUY THIS REPORT

---

Investors, biopharma, CDMOs, hospitals, payers, regulators, lenders and policymakers, and strategic corporate planners and decision-makers.

### Access the Full Report

The complete report delivers all 53 chapters in full, with every sub-heading, country table, company and patent directory, forecast model and due diligence checklist.

Purchase at [www.anewmarketdynamics.com](http://www.anewmarketdynamics.com) · Standard & Premium licences · Single-Site (SSL) and Global-Site (GSL) options at checkout.

### Want the Complete Detailed Table of Contents?

This prospectus lists the nine parts and 53 chapters. The complete detailed table of contents — every sub-heading, country table, exhibit, company and patent directory and annex — is available on request to registered users. To receive it, register with your official company email at [www.anewmarketdynamics.com](http://www.anewmarketdynamics.com). The full detailed table of contents will be sent directly to your registered company email address.